$KEQU

Noble Ryan S. sold (to issuer) $109K of KEQU

Noble Ryan S. (SVP, Sales & Marketing Dev) sold (to issuer) 3,000 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.11M total) on 2026-06-30.

Original reporting
SEC EDGAR · Noble Ryan S.
Published Jul 2, 2026, 3:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 3:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KEQU
Neutral
medium confidence
Mentioned
$KEQU
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KEQUNeutralLow
01

Why it matters

A named officer sold 3,000 shares to the issuer at $36.25; this is a primary-source disclosure but typically does not change fundamentals by itself.

02

Market read

Traders may note insider activity, but the disclosed transaction size and type suggest limited incremental information.

03

What to watch

Insider sales can be driven by liquidity/tax needs; without context on total compensation, prior sales, or whether the issuer transaction is part of a structured buyback program, signal strength is limited.

Relevance 4/10Novelty 3/10Timing: filed after-hours on 2026-07-02 (SEC EDGAR timestamp)

Background

The filing is a SEC Form 4 insider transaction for KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU).

Company-level read

Ticker impact

$KEQUNeutralMedium confidence
Context

KEQU disclosed an insider Form 4: SVP Noble Ryan S. sold 3,000 shares to the issuer at $36.25 on 2026-06-30.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

Form 4 insider transactions are typically informational but not usually market-moving unless tied to unusual circumstances; the article provides size ($108.75k) and transaction type (D sale to issuer) without broader corporate news.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as less “scheduled,” but the transaction is still a modest value and to the issuer, which often reduces interpretive weight.

Key entities

  • KEWAUNEE SCIENTIFIC CORP /DE/

    Company subject of the Form 4 insider transaction disclosure.

  • Noble Ryan S.

    SVP, Sales & Marketing Dev; sold shares to the issuer.

Related articles

$KEQUMed

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU): Results of Operations and Financial Condition

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 prfy26q4earningsrelease.htm EX-99.1 Document Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. June 23, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ